Nanomedicine Global Market to Observe Stupendous Growth at a CAGR of ~11% by 2028 | DelveInsight
Nanomedicine is experiencing heightened demand, mainly propelled by the increasing occurrence of chronic ailments like cardiovascular, neurological, inflammatory, and musculoskeletal diseases. The overall growth of the nanomedicine market from 2023 to 2028 is further fueled by augmented government support, a surge in funding, rising demand for therapies with minimal side effects, cost-effective treatment solutions, increased nano drug out-licensing, and a growing reliance on nanotechnology-based contrast reagents for diagnosis and monitoring pharmacological effects.
New York, USA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- *Nanomedicine Global Market to Observe Stupendous Growth at a CAGR of ~11% by 2028 | DelveInsight*
*Nanomedicine is experiencing heightened demand, mainly propelled by the increasing occurrence of chronic ailments like cardiovascular, neurological, inflammatory, and musculoskeletal diseases. The overall growth of the nanomedicine market from 2023 to 2028 is further fueled by augmented government support, a surge in funding, rising demand for therapies with minimal side effects, cost-effective treatment solutions, increased nano drug out-licensing, and a growing reliance on nanotechnology-based contrast reagents for diagnosis and monitoring pharmacological effects.*
DelveInsight’s *Nanomedicine Market Insights* report provides the current and forecast market analysis, individual leading nanomedicine companies’ market shares, challenges, nanomedicine market drivers, barriers, trends, and key market nanomedicine companies in the market.
*Key Takeaways from the Nanomedicine Market Report*
· As per DelveInsight estimates, North America is anticipated to dominate the global nanomedicine market during the forecast period.
· Notable nanomedicine companies such as *Sanofi, Pfizer Inc., Taiwan Liposome Company, Ltd., Johnson & Johnson, Bristol-Myers Squibb Company, Cytimmune Sciences, Inc., Luminex Corporation, Merck & Co., Inc., Starpharma Holdings Limited, Precision NanoSystems, Nanobiotix, Medtronic, Spago Nanomedical AB, Genetic Immunity, Nanospectra Biosciences,* and several others, are currently operating in the nanomedicine market.
· In *December 2023*, a team of researchers from the LKS Faculty of Medicine at the University of Hong Kong and collaborators at the Zhongshan Ophthalmic Centre of Sun Yat-sen University, Guangzhou, introduced a light-activatable prodrug nanomedicine designed for the treatment of age-related macular degeneration (AMD).
· In *March 2023, Moderna *collaborated with Generation Bio to use its proprietary cell-targeted lipid nanoparticle delivery system for the development of non-viral genetic medicines to treat immune systems and liver-related disorders.
To read more about the latest highlights related to the nanomedicine market, get a snapshot of the key highlights entailed in the *Global Nanomedicine Market Report*
*Nanomedicine Overview*
Nanomedicine is a cutting-edge interdisciplinary field at the intersection of nanotechnology and medicine, aiming to revolutionize the way we diagnose, treat, and prevent diseases at the molecular and cellular levels. By harnessing the unique properties of materials at the nanoscale, scientists and researchers in nanomedicine strive to develop innovative solutions for healthcare challenges. Nanoparticles, nanodevices, and nanomaterials play pivotal roles in this field, offering the potential for targeted drug delivery, enhanced imaging, and precise therapeutic interventions. The ability of nanomedicine to navigate the complexities of the human body at a molecular level holds promise for personalized medicine, minimizing side effects and optimizing treatment outcomes. As researchers continue to explore the vast possibilities within nanomedicine, its applications span a wide range of medical areas, from cancer therapy and infectious disease management to regenerative medicine and diagnostics, ushering in a new era of healthcare with unprecedented precision and effectiveness.
*Nanomedicine Market Insights *
In 2022, North America emerged as the leading market for nanomedicine, largely driven by its extensive utilization in early disease detection, preventive care, and management of chronic and acute ailments. The region's robust regulatory structure facilitating swift product approvals and commercialization has significantly contributed to this dominance. Concurrently, key industry players have been innovating and forging strategic partnerships to elevate their market presence. Notably, SPI Medical and Nano-X Imaging collaborated in 2020 to introduce Nanox’s state-of-the-art X-ray systems in Mexico, employing semiconductor-based Nanox ARC technology, surpassing traditional cathode ray tube models.
Furthermore, in August 2020, Innovasis Inc., in partnership with Promimic, received FDA clearance to introduce 3D-printed implants for spinal fusion surgery. These implants incorporate Promimic's HAnano Surface Technology, enhancing molecular adhesion for improved implant integration.
To know more about why North America is leading the market growth in the nanomedicine market, get a snapshot of the *Nanomedicine Market Outlook*
*Nanomedicine Market Dynamics*
The nanomedicine market is growing in response to heightened product demand, primarily fueled by the *increasing incidence of chronic diseases*, including cancers, cardiovascular issues, and neurological disorders. A notable feature of nanomedicine is its capacity to selectively target cancerous cells and neoplasms. This targeted approach enables clinicians to safely administer *chemotherapy, radiotherapy, and advanced immuno and gene therapies* to tumors. Nanomedicines play a role in improving anticancer therapy by modifying pharmacology and *enhancing tissue distribution* at the site of action. However, the growth trajectory of the nanomedicine market may face obstacles, including *inherent drawbacks of nanomedicine* and the challenges posed by *stringent regulatory procedures*.
Get a sneak peek at the nanomedicine market dynamics @ *Nanomedicine Market Dynamics Analysis*
*Report Metrics* *Details*
Coverage Global
Study Period 2020–2028
Nanomedicine Market CAGR ~11%
Key Nanomedicine Companies Sanofi, Pfizer Inc., Taiwan Liposome Company, Ltd., Johnson & Johnson, Bristol-Myers Squibb Company, Cytimmune Sciences, Inc., Luminex Corporation, Merck & Co., Inc., Starpharma Holdings Limited, Precision NanoSystems, Nanobiotix, Medtronic, Spago Nanomedical AB, Genetic Immunity, Nanospectra Biosciences, among others
*Nanomedicine Market Assessment*
· *Nanomedicine Market Segmentation*
· *Nanomedicine Market Segmentation By Molecule Type: *Nanoparticle, Nanoshells, Nanotubes, and Nanodevices
· *Nanomedicine Market Segmentation By Application: *Drug Delivery, Implants, Diagnostic Imaging, Biomaterials, and Others
· *Nanomedicine Market Segmentation By Indication: *Cardiovascular, Oncology, Neurology, Orthopaedic, Infectious, and Others
· *Nanomedicine Market Segmentation By Geography*: North America, Europe, Asia-Pacific, and Rest of World
· *Porter’s Five Forces Analysis, Product Profiles, **Case Studies, KOL’s Views, Analyst’s View*
Which MedTech key players in the nanomedicine market are set to emerge as the trendsetter explore @ *Nanomedicine Companies** *
*Table of Contents *
1 Report Introduction
2 Executive summary
3 Regulatory and Patent Analysis
4 Key Factors Analysis
5 Porter’s Five Forces Analysis
6 COVID-19 Impact Analysis on Nanomedicine Market
7 Nanomedicine Market Layout
8 Global Company Share Analysis – Key 3-5 Companies
9 Nanomedicine Market Company and Product Profiles
10 Project Approach
11 About DelveInsight
Interested in knowing the nanomedicine market by 2028? Click to get a snapshot of the *Nanomedicine Market Trends*
*Related Reports*
*Non-Small Cell Lung Cancer Market*
*Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 *report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including *EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma*, among others.
*Glioblastoma Market*
*Glioblastoma Market Insights, Epidemiology, and Market Forecast – 2032 *report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glioblastoma companies, including *Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Biotherapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, TME Pharma, Novocure, Genentech, Daiichi Sankyo, Novartis*, among others.
*Oncolytic Cancer Therapies Market*
*Oncolytic Cancer Therapies Market Insights, Epidemiology, and Market Forecast – 2032 *report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key oncolytic cancer therapies companies, including *Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichi Sankyo*, among others.
*Multiple Myeloma Market*
*Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2032 *report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including *Johnson & Johnson (Janssen), Pfizer, AbbVie and Roche (Genentech), Regeneron Pharmaceuticals, Bristol-Myers Squibb, Celgene, Roche (Genentech), Arcellx, Novartis, Regeneron Pharmaceuticals, BeiGene, CARsgen Therapeutics, Cartesian Therapeutics, C4 Therapeutics, Heidelberg Pharma, Bristol-Myers Squibb, RAPA Therapeutics, AbbVie (TeneoOne), Takeda*, among others.
*Triple-Negative Breast Cancer Market*
*Triple-Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2032 *report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key TNBC companies, including *HiberCell, Hoffmann-La Roche, Infinity Pharmaceuticals, CytoDyn, Medicenna Therapeutics, Eli Lilly and Company, Tesaro, Inc., Merck Sharp & Dohme LLC, Gilead Sciences, NBE-Therapeutics AG, Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Inc., SynDevRx, Inc., GlaxoSmithKline, AstraZeneca, BioEclipse Therapeutics, Precigen, Inc, Clovis Oncology, Inc., Takeda, ModernaTX, Inc., Arcus Biosciences, Inc., Rapa Therapeutics LLC, BeiGene, OncXerna Theraputics, Inc., Jacobio Pharmaceuticals Co., Ltd., Novartis Pharmaceuticals, Astex Pharmaceuticals, Inc., A&G Pharmaceutical Inc., Zenith Epigenetics, Ayala Pharmaceuticals, Inc., Phoenix Molecular Designs, Celldex Therapeutics, CytomX Therapeutics, Exelixis, BioAtla, Inc., Sellas Life Sciences Group, AbbVie, BioNTech SE, Mundipharma Research Limited, NeoImmuneTech, Sanofi, Kymab Limited*, among others.
*About DelveInsight*
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
CONTACT: Contact Us
Shruti Thakur
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/medical-devices